Ziprasidone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (32)
Bipolar Disorder
NCT03768726 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2018-12-21 – 2020-07-31 · Bipolar Disorder
What this study did
NCT02075047 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2014-05-23 – 2020-05-18 · Bipolar Disorder
What this study did
NCT01124877 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-07 – 2011-10 · Bipolar Disorder
What this study did
NCT01117220 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-06 – 2011-04 · Bipolar Disorder
What this study did
NCT01113541 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-07 – 2011-02 · Bipolar Disorder
What this study did
NCT00421954 · New York State Psychiatric Institute
2006-05 – 2009-05 · Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
What this study did
NCT00288353 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00483548 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-10 – 2008-12 · Bipolar Disorder, Depression, Bipolar
What this study did
NCT00280566 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-12 – 2008-05 · Bipolar Mania, Bipolar Disorder
What this study did
NCT00282464 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-02 – 2008-03 · Bipolar Disorder
What this study did
NCT00141271 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-07 – 2008-02 · Bipolar Disorder
What this study did
NCT00265330 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-03 – 2008-01 · Bipolar Disorder
What this study did
NCT00257166 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-01 – 2007-07 · Bipolar Disorder
What this study did
Schizophrenia
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00723606 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-09 – 2009-07 · Schizophrenia
What this study did
NCT00265382 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-06 – 2009-06 · Schizophrenia
What this study did
NCT00139737 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2002-03 – 2009-06 · Schizophrenia
What this study did
NCT00257192 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-04 – 2009-03 · Schizophrenia
What this study did
NCT00174447 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-10 – 2008-10 · Schizophrenia
What this study did
NCT00347425 · Solvay Pharmaceuticals
2006-12 – 2008-02 · Schizophrenia and Schizoaffective Disorder
What this study did
NCT00136994 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-03 – 2005-11 · Schizophrenia
What this study did
NCT00145444 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-03 – 2005-11 · Schizophrenia, Psychotic Disorders
What this study did
NCT00143351 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-06 – 2005-09 · Schizophrenia
What this study did
NCT00645372 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-07 – 2005-05 · Schizophrenia
What this study did
NCT00645229 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-09 – 2005-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00649844 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-01 – 2004-09 · Schizophrenia
What this study did
NCT00645515 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-06 – 2003-12 · Schizophrenia
What this study did
Other / comorbidity
NCT01211522 · Vanderbilt University Medical Center
2011-12-14 – 2018-07-19 · Delirium, Impaired Cognition, Long Term Psychologic Disorders
What this study did
NCT00197951 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2004-10 – 2007-04 · Depression, Anger, Anxiety, Alcoholism
What this study did
Phase 2/3 (2)
Schizophrenia
NCT00395031 · Manhattan Psychiatric Center
2003-09 – 2010-01 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT00340379 · Duke University
2003-04 – 2005-08 · Affective Disorders
What this study did
Phase 2 (11)
Bipolar Disorder
NCT00490542 · Tufts Medical Center
2006-12 – 2009-08 · Bipolar Disorder, Bipolar Depression, Depression
What this study did
NCT00650611 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-12 – 2005-03 · Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
What this study did
Schizophrenia
NCT01006551 · University of North Carolina, Chapel Hill
2002-12 – 2006-02 · Schizophrenia
What this study did
Other / comorbidity
NCT00633399 · Massachusetts General Hospital
2008-07 – 2014-03 · Major Depressive Disorder
What this study did
NCT00635700 · Yale University
2008-03 – 2012-11 · Psychosis Prodrome
What this study did
NCT00555997 · Massachusetts General Hospital
2008-03 – 2010-06 · Major Depressive Disorder
What this study did
NCT00215150 · Duke University
2004-11 – 2009-07 · Social Anxiety Disorder
What this study did
NCT00676429 · University Hospital Freiburg
2006-07 – 2008-06 · Conduct Disorder, Oppositional Defiant Disorder
What this study did
NCT00096863 · Vanderbilt University
2004-12 – 2007-07 · Delirium, Cognition Disorders
What this study did
NCT00208559 · Drexel University College of Medicine
2002-02 – 2006-08 · Autism
What this study did
NCT00635921 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2004-03 – 2006-04 · Borderline Personality Disorder
What this study did
Phase 1/2 (1)
Schizophrenia
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
Phase 1 (6)
Schizophrenia
NCT03781115 · University of Arizona
2017-11-20 – 2027-02-10 · Schizophrenia
What this study did
Other / comorbidity
NCT03837860 · The University of Texas Health Science Center at San Antonio
2019-04-01 – 2022-01-21 · Opioid Abuse, Unspecified, Opioid Dependence
What this study did
NCT03011645 · Duke University
2018-05-24 – 2020-01-28 · Cardiovascular Diseases
What this study did
NCT04587115 · The University of Texas Health Science Center at San Antonio
2017-06-16 – 2020-01-01 · Addiction
What this study did
NCT01581866 · Dr. Reddy's Laboratories Limited
2004-11 – 2005-01 · Healthy
What this study did
NCT01581879 · Dr. Reddy's Laboratories Limited
2004-11 – 2005-01 · Healthy
What this study did
Phase 4 (47)
Bipolar Disorder
NCT01893229 · Guiyun Xu
2013-09 – 2015-12 · Bipolar Disorder
What this study did
NCT01293825 · University Hospitals Cleveland Medical Center
2011-01 – 2012-08 · Medication Adherence, Bipolar Disorder
What this study did
NCT01168674 · Tufts Medical Center
2010-02 – 2011-12 · Depression, Bipolar Disorder
What this study did
NCT01172652 · VA Palo Alto Health Care System
2010-04 – 2011-10 · Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
What this study did
NCT00472641 · Stanford University
2007-01 – 2009-12 · Bipolar Disorder
What this study did
NCT00622739 · Baylor College of Medicine
2007-02 – 2009-11 · Bipolar Disorder
What this study did
NCT00374543 · Massachusetts General Hospital
2006-02 – 2008-11 · Generalized Anxiety Disorder, Bipolar Disorder
What this study did
NCT00237666 · The Medical Research Network
2005-02 – 2008-02 · Bipolar II Disorder, Major Depressive Episode
What this study did
NCT00329108 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-11 – 2008-01 · Acute Mania, Bipolar Disorder, Manic
What this study did
NCT00048802 · Northwell Health
2002-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00181922 · Massachusetts General Hospital
2002-03 – 2004-12 · Bipolar Disorder, Mania
What this study did
Schizophrenia
NCT04446234 · Shanghai Mental Health Center
2021-05 – 2022-12-31 · Schizophrenia
What this study did
NCT02935998 · Yang Fude
2016-10 – 2017-12 · Schizophrenia
What this study did
NCT01185743 · Medical University of Vienna
2010-07 – 2017-01-01 · Schizophrenia, Diabetes
What this study did
NCT02307396 · Technical University of Munich
2015-02-01 – 2016-06-22 · Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
What this study did
NCT02526030 · Fundación Marques de Valdecilla
2008-10 – 2015-06 · Schizophrenia, Psychotic Disorders
What this study did
NCT02305823 · Fundación Marques de Valdecilla
2005-10 – 2014-05 · Schizophrenia, Psychotic Disorders
What this study did
NCT01198353 · Soonchunhyang University Hospital
2010-09 – 2013-12 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT02534363 · Fundación Marques de Valdecilla
2005-10 – 2013-01 · Schizophrenia, Psychotic Disorders
What this study did
NCT00748566 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-12 – 2012-05 · Schizophrenia and Disorders With Psychotic Features
What this study did
NCT01714011 · University of Malaya
2009-05 – 2011-09 · Schizophrenia
What this study did
NCT00338949 · Veterans Medical Research Foundation
2006-06 – 2009-12 · Schizophrenia, Metabolic Syndrome X, Insulin Resistance
What this study did
NCT00406315 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-11 – 2009-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00044655 · Icahn School of Medicine at Mount Sinai
2001-07 – 2009-03 · Schizophrenia
What this study did
NCT00458211 · Bronx Psychiatric Center
2005-05 – 2008-04 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00148564 · Charite University, Berlin, Germany
2004-03 – 2007-06 · Schizophrenia
What this study did
NCT00199940 · Medical College of Wisconsin
2003-12 – 2007-04 · Schizophrenia, Affective Disorders, Psychotic Disorder, Psychotic Mood Disorder
What this study did
NCT00418171 · Pfizer
2002-02 – 2007-04 · Schizophrenia
What this study did
NCT00351000 · North Suffolk Mental Health Association
2005-01 – 2007-03 · Schizophrenia
What this study did
NCT00239109 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-04 – 2007-02 · Schizophrenia
What this study did
NCT00224315 · Central Institute of Mental Health, Mannheim
2003-11 – 2006-09 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00137020 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-11 – 2006-04 · Schizophrenia, Psychotic Disorders
What this study did
NCT00650429 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-10 – 2005-05 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00634348 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-04 – 2005-03 · Schizophrenia
What this study did
NCT00159757 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-11 – 2005-02 · Schizophrenia
What this study did
NCT00014001 · National Institute of Mental Health (NIMH)
2000-12 – 2004-12 · Schizophrenia
What this study did
NCT00649064 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-12 – 2004-09 · Schizoaffective Disorder, Schizophrenia
What this study did
NCT00644800 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-07 – 2004-05 · Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
What this study did
NCT00034801 · Eli Lilly and Company
2001-09 – 2003-03 · Depression, Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT01844700 · Northwell Health
2013-07 – 2014-04 · High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
What this study did
NCT00786318 · George Washington University
2008-09 – 2011-07 · Psychosis, Agitation, Delirium
What this study did
NCT00835107 · Queen's University
2009-02 – 2011-06 · Depression, Bipolar
What this study did
NCT01157559 · Chonbuk National University Hospital
est. completion 2010-05 · First Episode Psychosis
What this study did
NCT00932529 · University of Bergen
2003-02 – 2010-01 · Psychotic Disorders
What this study did
NCT00297960 · Medical University of Vienna
started 2005-04 · Healthy Male Volunteers
What this study did
NCT00208208 · Creighton University
2002-12 – 2005-04 · Posttraumatic Stress Disorder, Post-Traumatic Stress Disorder, PTSD
What this study did
NCT00645320 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-08 – 2004-08 · Pyschotic Disorders
What this study did
Early phase / not applicable (10)
Bipolar Disorder
NCT00538642 · The University of Texas Health Science Center at San Antonio
2007-08 – 2011-11 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00288366 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
Schizophrenia
NCT04076371 · Beijing HuiLongGuan Hospital
2012-01 – 2018-12 · Schizophrenia
What this study did
NCT00818298 · Centre for Addiction and Mental Health
2009-01 – 2011-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00229385 · Sheba Medical Center
2006-01 – 2010-04 · Schizophrenia, Obsessive Compulsive Disorder
What this study did
NCT00515723 · Washington University School of Medicine
2001-09 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
What this study did
NCT00225498 · Northwell Health
2002-06 – 2008-10 · Schizophrenia
What this study did
NCT00205725 · Washington University School of Medicine
2000-11 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT00910988 · Washington University School of Medicine
2009-02 – 2012-06 · Hyperglycemia, Hyperlipidemia
What this study did
NCT01485692 · University of Sao Paulo
2009-02 – 2011-03 · Psychomotor Agitation
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Schizophrenia
NCT00254202 · Vanda Pharmaceuticals
2005-11-18 – 2007-03-21 · Schizophrenia
What this study did
Phase 1 (1)
Other / comorbidity
NCT00821444 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-01 – 2009-03 · Healthy
What this study did
Phase 4 (3)
Schizophrenia
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did
Early phase / not applicable (1)
Schizophrenia
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Phase 4 (1)
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ziprasidone: this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ziprasidone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 1SchizophreniaActive not recruiting
Est. primary completion 2027-02-10 · NCT03781115 · CT.gov ↗
What to watch

See the full readout calendar ↗